1. Home
  2. MDGL vs WH Comparison

MDGL vs WH Comparison

Compare MDGL & WH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDGL
  • WH
  • Stock Information
  • Founded
  • MDGL 2011
  • WH 2017
  • Country
  • MDGL United States
  • WH United States
  • Employees
  • MDGL N/A
  • WH N/A
  • Industry
  • MDGL Biotechnology: Pharmaceutical Preparations
  • WH Hotels/Resorts
  • Sector
  • MDGL Health Care
  • WH Consumer Discretionary
  • Exchange
  • MDGL Nasdaq
  • WH Nasdaq
  • Market Cap
  • MDGL 7.5B
  • WH 8.5B
  • IPO Year
  • MDGL N/A
  • WH N/A
  • Fundamental
  • Price
  • MDGL $323.98
  • WH $90.97
  • Analyst Decision
  • MDGL Buy
  • WH Strong Buy
  • Analyst Count
  • MDGL 10
  • WH 11
  • Target Price
  • MDGL $354.75
  • WH $116.36
  • AVG Volume (30 Days)
  • MDGL 317.3K
  • WH 1.2M
  • Earning Date
  • MDGL 05-06-2025
  • WH 04-23-2025
  • Dividend Yield
  • MDGL N/A
  • WH 1.80%
  • EPS Growth
  • MDGL N/A
  • WH 5.87
  • EPS
  • MDGL N/A
  • WH 3.61
  • Revenue
  • MDGL $180,133,000.00
  • WH $1,404,000,000.00
  • Revenue This Year
  • MDGL $228.41
  • WH $9.83
  • Revenue Next Year
  • MDGL $73.44
  • WH $7.33
  • P/E Ratio
  • MDGL N/A
  • WH $25.24
  • Revenue Growth
  • MDGL N/A
  • WH 1.45
  • 52 Week Low
  • MDGL $189.00
  • WH $67.67
  • 52 Week High
  • MDGL $377.46
  • WH $113.07
  • Technical
  • Relative Strength Index (RSI)
  • MDGL 45.41
  • WH 37.85
  • Support Level
  • MDGL $310.00
  • WH $87.70
  • Resistance Level
  • MDGL $350.50
  • WH $93.58
  • Average True Range (ATR)
  • MDGL 13.02
  • WH 2.59
  • MACD
  • MDGL -1.72
  • WH 0.30
  • Stochastic Oscillator
  • MDGL 34.52
  • WH 61.33

About MDGL Madrigal Pharmaceuticals Inc.

Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.

About WH Wyndham Hotels & Resorts Inc.

As of Dec. 31, 2024, Wyndham Hotels & Resorts operates 903,000 rooms across more than 20 brands predominantly in the economy and midscale segments. Super 8 is the largest brand, representing around 18% of all rooms, with Days Inn (13%) and Ramada (14%) the next two largest brands. During the past several years, the company has expanded its extended stay/lifestyle brands, which appeal to travelers seeking to experience the local culture of a given location. The company closed its La Quinta acquisition in the second quarter of 2018, adding around 90,000 rooms at the time the deal closed. Wyndham launched a new extended stay economy scale segment concept, ECHO, in the spring of 2022. The United States represents 56% of total rooms.

Share on Social Networks: